stockportfolio.pro
Stocks / GMAB vs JAZZ
GMAB vs JAZZ
Genmab A/S and Jazz Pharmaceuticals plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Genmab A/S (GMAB) | Jazz Pharmaceuticals plc (JAZZ) | |
|---|---|---|
| Market cap | $15.3B | $14.4B |
| Revenue (latest FY) | $3.72B | $4.27B |
| Net income (latest FY) | $963.00M | $-356.15M |
| Revenue growth (5y CAGR) | 21.2% | 12.5% |
| Net margin | 25.9% | -8.3% |
| Return on equity | 16.5% | -8.2% |
| P/E ratio | 19.1 | 2080.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 4 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GMAB — free Open JAZZ — freeFrequently asked questions
Which is bigger, GMAB or JAZZ?
Genmab A/S is larger by market capitalization — $15.3B versus $14.4B.
Which grows faster, GMAB or JAZZ?
Over the last five fiscal years, Genmab A/S grew revenue faster — 21.2%/yr versus 12.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.